FDA
-
-
-
-
-
-
-
Cytokinetics to Participate in June Investor Conferences
-
-
-
-
-
-
-
Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Cytokinetics to Announce First Quarter Results on May 5, 2026
-
-
-
-
-
-
-
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
-
-
-
-
-
-
-
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Graba
-
-
-
-
-
-
-
Cytokinetics (CYTK) PT Raised to $84 at Needham
-
-
-
-
-
-
-
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
-
326,260 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

